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Abstract
The transforming JAK2V617F kinase is frequently associated with myeloproliferative neoplasms
(MPNs) and thought to be instrumental for the overproduction of myeloid lineage cells. Several
small molecule drugs targeting JAK2 are currently in clinical development for treatment in these
diseases. We performed a high-throughput in vitro screen to identify point mutations in
JAK2V617F that would be predicted to have potential clinical relevance and associated with drug
resistance to the JAK2 inhibitor ruxolitinib (INCB018424). Seven libraries of mutagenized
JAK2V617F cDNA were screened to specifically identify mutations in the predicted drug-binding
region that would confer resistance to ruxolitinib, using a BaF3 cell-based assay. We identified 5
different non-synonymous point mutations that conferred drug resistance. Cells containing
mutations had a 9 to 33-fold higher EC50 for ruxolitinib compared to native JAK2V617F. Our
results further indicated that these mutations also conferred cross-resistance to all JAK2 kinase
inhibitors tested, including AZD1480, TG101348, lestaurtinib (CEP-701) and CYT-387.
Surprisingly, introduction of the ‘gatekeeper’ mutation (M929I) in JAK2V617F affected only
ruxolitinib sensitivity (4-fold increase in EC50). These results suggest that JAK2 inhibitors
currently in clinical trials may be prone to resistance as a result of point mutations and caution
should be exercised when administering these drugs.
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Introduction
Myeloproliferative neoplasms (MPNs) are frequently associated with a mutation in the non-
receptor tyrosine kinase JAK2 at codon 617 that changes valine (V) to phenylalanine (F).
This activating JAK2V617F mutation is not only found in the majority of patients with
myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia,
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idiopathic myelofibrosis, but can also be present at lower frequency in other myeloid
malignancies, including acute myeloid leukemia and myelodysplastic syndromes 1.
JAK2V617F is thought to be instrumental for the overproduction of myeloid lineage cells
and in mice it is sufficient by itself to cause a myeloproliferative disease 2. Even though the
crystal structure of the JAK2 kinase domain has been solved 3, 4, it is not known how
exactly the V617F mutation in the pseudokinase domain leads to constitutive activation. The
JAK2V617F mutation seems insufficient for its kinase activation and association with a
cytokine receptor, such as the erythropoietin receptor (EpoR) appears to be required 5. Lack
of a functional FERM domain in JAK2V617F, which mediates interaction with cytokine
receptors, results in a loss of its transforming activity 6. It is likely that inhibitory
constraints, normally overcome by ligand binding, are targeted by the JAK2V617F
mutation, therefore leading to hyperresponsiveness or factor-independent growth.
One of the first JAK2 inhibitors entering clinical trials for the treatment of myelofibrosis
was ruxolitinib (INCB018424). This drug has shown significant efficacy and dose-limiting
toxicity is thrombocytopenia 7. Nevertheless, it is expected that there are additional activities
that may lead to specific toxic effects, such as dose-limiting hyperamylasaemia with
TG101348 and other effects with related drugs 8, 9. Like other JAK2 inhibitors, including
TG101348, AZD1480 and CYT-387, ruxolitinib displays activity against the related
JAK1 10-14. In contrast, the JAK2 inhibitor lestaurtinib (CEP-701) is structurally related to
the pan protein kinase inhibitor staurosporine and also shows activity against FLT3, RET
and Trk family members 15-18. All inhibitors tested for myelofibrosis demonstrated efficacy
with a reduction of splenomegaly, including ruxolitinib, lestaurtinib, CYT-387, SB1518 and
TG101348 9. There are additional JAK2 inhibitors at various stages in clinical trials for the
treatment of MPNs and their toxicity and efficacy is currently under investigation 9.
Most, if not all, tyrosine kinase inhibitors that are currently used to target transforming
tyrosine kinase oncogenes in various cancers are susceptible to resistance, as a result of
point mutations in the corresponding kinase domain 19-23. We sought to investigate whether
mutations in the JAK2 JH1 domain would confer resistance and compare the sensitivity of
different inhibitors that are currently in clinical trials towards these mutations. Using the
JAK2 inhibitor ruxolitinib in our primary screen, we identified five different non-
synonymous point mutations in JAK2V617F that conferred drug resistance. We also
observed cross-resistance between all mutations and five different JAK2 inhibitors tested. In
addition, an analysis of the ruxolitinib-docked JAK2 structure was performed to identify
potential sites of drug-target interaction. Interestingly, introduction of the M929I
‘gatekeeper’ mutation in JAK2V617F lead to ruxolitinib resistance only. Point mutations in
the JAK2 kinase domain may provide a significant obstacle and it would be predicted that
drugs currently in clinical development may not be sufficient to overcome resistance. It will
now be interesting to determine whether these mutations occur in patients that fail to
respond to JAK2 inhibitors in clinical trials.
Materials And Methods
Cells
The murine pre-B BaF3 cell line expressing the erythropoietin receptor (EpoR) was
maintained in RPMI 1640 (Mediatech, Manassas, VA) containing 10% fetal bovine serum
(FBS; Lonza, Walkersville, MD), supplemented with WEHI-3B conditioned medium under
a 5% CO2 atmosphere. In some experiments, cells were treated with kinase inhibitors,
including ruxolitinib (INCB018424), TG101348 (both Active Biochemicals, Hong Kong,
China), CYT-387 (ChemieTek, Indianapolis, IN), AZD1480 (Selleck, Houston, TX) and
lestaurtinib (CEP701, Tocris Bioscience Ellisville, MO). Cell growth in response to various
drug concentrations was measured by trypan blue (Sigma) exclusion or with the CellTiter
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96® AQueous One Solution Cell Proliferation Assay reagent (Promega, Madison, WI). The
CalcuSyn (Biosoft, Great Shelford, United Kingdom) analysis program was used to estimate
drug concentrations resulting in 50% inhibition (EC50), compared to control treated cells.
Random mutagenesis of JAK2V617F
Random mutations were introduced into the pMSCV.JAK2V617F.IRES.GFP construct
using the mutT (unable to hydrolyze 8-oxodGTP), mutS (error-prone mismatch repair) and
mutD (deficient in 3′- to 5′-exonuclease of DNA polymerase III) deficient XL1-Red E.coli
strain, according to the manufacturer's protocol (Agilent, Santa Clara, CA). A total of seven
different libraries of mutagenized JAK2V617F were generated.
Identification of cells resistant to ruxolitinib
Mutagenized JAK2V617F libraries were used to prepare retroviral supernatants 6 to infect
BaF3 cells expressing the erythropoietin receptor (BaF3.EpoR). Cells were expanded for at
least three days and pretreated with 1.44 μM ruxolitinib (12 times the EC50 in parental cells)
for two days before sorting of single GFP-expressing cells into 96-well plates. Resistant
colonies were isolated in the presence of 1.44 μM ruxolitinib.
Detection of mutations in the JAKV617F kinase domain
Genomic DNA was isolated (QIAmp DNA Blood kit, Qiagen, Germantown, MD) from drug
resistant colonies and the putative drug binding region in the kinase domain amplified by
PCR (AccuPrime Pfx, Invitrogen, Carlsbad, CA) using standard methods and specific
primers (forward: 5′-ATGAGCCAGATTTCAGGCCTGCTT-3′; reverse 5′-
AGAAAGTTGGGCATCACGCAGCTA-3′) on a MJ Research PTC-200 Peltier Thermal
Cycler (St. Bruno, Canada). DNA sequencing was performed at the DFCI Molecular
Biology Core Facility (forward PCR primer or 5′-ACATGAGAATAGGTGCCCTAGG-3′)
and ambiguous results were confirmed by sequencing of the reverse strand (not shown).
Identified mutations were reintroduced into JAK2V617F by site-directed mutagenesis using
the QuikChange II XL Mutagenesis Kit (Agilent) and specific mutagenesis primers,
according to the manufacturer's protocol. The entire cDNA sequence of the mutagenized
product was verified by DNA sequencing (not shown).
Characterization of cell lines expressing mutated JAK2V617F
BaF3.EpoR cell lines expressing potential drug resistant mutant JAK2V617F were generated
by retroviral infection, as described previously 6. Stable transfectants were sorted for GFP+
cells and the presence of the mutation confirmed by DNA sequencing of the putative drug-
binding site, as described above. Polyclonal populations of these cells were used to
determine changes in growth in response to various JAK2 inhibitors.
Docking of ruxolitinib to JAK2 and structure analysis
The three-dimensional structure of INCB018424 (PubChem: CID 25126798) was docked
onto the monomer three-dimensional structure of JAK2 extracted from the CMP6-bound
JAK2 crystal structure (PDB ID: 2B7A) 3. Docking calculations were carried out using
DockingServer 24. Gasteiger partial charges were added to the ligand atoms. Non-polar
hydrogen atoms were merged, and rotatable bonds were defined. Essential hydrogen atoms,
Kollman united atom type charges, and solvation parameters were added with the aid of
AutoDock tools 25. To limit the docking simulations to the inhibitor-binding pocket,
determined from the CMP6-JAK2 structure, the affinity grid was set to fit the inhibitor-
binding pocket. AutoDock parameter set- and distance-dependent dielectric functions were
used in the calculation of the van der Waals and the electrostatic terms, respectively.
Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and
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the Solis & Wets local search method as applied in the DockingServer 24. Initial position,
orientation, and torsions of the ligand molecules were set randomly. All rotatable torsions
were released during docking. Each docking experiment was derived from 2 different runs
that were set to terminate after a maximum of 250,000 energy evaluations. The population
size was set to 150. During the search, a translational step of 0.2 Å, and quaternion and
torsion steps of 5 were applied. The best scoring docking pose of ruxolitinib-JAK2 was used
for the drug-target interface analysis in PyMOL (http://www.pymol.org) and structure
figures were rendered using PyMOL.
Immunoblotting
Immunoblotting was performed using a standard chemiluminescence technique, as described
previously 26. Rabbit polyclonal antibodies against STAT5 (Santa Cruz Biotechnology,
Santa Cruz, CA), phospho-STAT5 (Y694 - Cell Signaling, Danvers, MA) or a mouse
monoclonal antibody against β-actin (AC-15; Sigma) were used.
Results
Identification of novel mutations in JAK2V617F that cause ruxolitinib resistance
In this study, we performed a screen for ruxolitinib resistant JAK2V617F mutations using a
mutagenesis strategy with a repair deficient E. coli strain, similar to previously described
approaches 27, 28. Seven independent libraries of mutated JAK2V617F expression vector
were generated and expressed in BaF3.EpoR cells. Our approach was specifically designed
to look for mutations in the predicted drug binding region of JAK2. In preliminary
experiments, resistant clones were initially selected at 3-, 6- and 12-times the EC50 of
ruxolitinib (0.36 μM, 0.72 μM and 1.44 μM, respectively). Only the highest ruxolitinib (1.44
μM) concentration was sufficient to allow for the identification of resistant mutations at a
frequency >10% of total. We isolated 128 independent resistant clones, but the majority of
clones did not contain a mutation in the sequenced region and the mechanism of resistance
was not further investigated. Overall, we identified five different point mutations, including
Y931C (Tyr931Cys), G935R (Gly935Arg), R938L (Arg938Leu), I960V (Ile960Val) and
E985K (Glu985Lys).
Structural analysis of JAK2V617F kinase domain mutations
The crystal structure for JAK2-bound ruxolitinib is not available and we therefore
performed docking simulations of this drug onto the monomer JAK2 structure, extracted
from the crystal structure of the JAK2-CMP6 complex. Published structures of JAK2 bound
to CMP6 3 and CP690,550 4 provide important clues on the mode of binding and
interactions between the related JAK2 inhibitors and the protein. Both CMP6 and
CP690,550 bind in the ATP-binding pocket of JAK2. With this in mind, we set the
parameters to preferentially simulate ruxolitinib docking positions in the CMP6 and
CP690,550 binding pocket on JAK2. The best scoring docking pose, with least estimated
free energy of binding (-9.05 kCal/mol), best estimated inhibition constant (KI of 231.83nM)
and highest interaction interface area (567.6 Å2), was used for the inhibitor-JAK2 interface
analysis. Ruxolitinib snugly fits into the ATP-binding pocket of JAK2 similar to CMP6 and
CP690,550, with the cyclopentyl and pyrazol rings tightly fitting in the deep hydrophobic
groove (Figure 1A). JAK2-ruxolitinib interaction interface buries most of the surface area of
the inhibitor. The inhibitor is held in the pocket by polar contacts between cyclopentyl ring
and mainchain atoms in the hinge region (between Y931 and L932), and also
pyrrolopyrimidine moiety with N981 sidechain. Ruxolitinib may also form hydrogen bonds
with water molecules in the pocket. Ruxolitinib makes extensive hydrophobic interactions
with several residues that line the binding pocket, similar to what was observed for CMP6
and CP690,550. A880, L855, V863 and M929 hold the inhibitor tight from the top and L932
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from the hinge region holds it from the side. Further, V911 and L983 provide hydrophobic
interactions from the bottom (Figure 1B, left panel). The pyrazol ring of ruxolitinib is in a
distance to have π–π interaction with the Y931 ring. Most mutations that were identified in
our screen are either interacting residues with ruxolitinib or in proximity of the binding
pocket (Figure 1B, right panels) and hence are likely to alter the inhibitor binding. Y931
seems to be a critical residue for inhibitor-protein interaction as its side chain and mainchain
atoms have interactions with the inhibitor. The Y931C mutation might disrupt the π–π
interaction between tyrosine ring and the inhibitor ring structure, thus weakening the
inhibitor binding and resulting in easy expulsion from the pocket. The G935R mutation
pushes a large charged sidechain towards the mouth of the hydrophobic cavity (Figure 1B,
right), which results in a strong positive charge at the corner of the binding pocket,
compared to the native protein (Figure 1C). The exact mechanism by which the R938L
(Figure 1B, right) and I960V mutations may effect the inhibitor binding cannot easily be
explained based on our computational analysis of the structure, but these two residues lie
near the binding pocket (R938L at the end of the hinge region and I960V in close proximity
of the binding pocket). The E985K mutation could bring the sidechain very close to the
inhibitor-binding site and result in charge repulsion of the inhibitor.
Ruxolitinib-resistant mutations display cross-resistance to other JAK2 tyrosine kinase
inhibitors
In order to confirm that the mutants identified in our screen truly conferred drug resistance,
they were reintroduced into JAK2V617F and expressed in BaF3.EpoR cells. All cell lines
generated, spontaneously converted into growth factor independence (not shown).
Consistent with our structural analysis, we found that both the Y931C as well as the G935R
mutation resulted in the largest increase (33.3-fold and 19.5-fold, respectively) in EC50
values, compared to native JAK2V617F (Figure 2A). The increase in EC50 values of
ruxolitinib for the R938L (12.7-fold), I960V (11.5-fold) and the E985K (9.0-fold) mutation
containing cells was somewhat lower. These data are also consistent with our screening
approach, allowing survival and outgrowth of resistant colonies at 1.44 μM ruxolitinib. We
next asked whether these mutations would also affect the sensitivity of other JAK2 tyrosine
kinase inhibitors (Figure 2B). In contrast to ruxolitinib, there was a comparable increase in
drug resistance for all mutations in response to CYT-387 (5.1 to 7.4-fold increase in EC50),
TG101348 (2.2 to 2.8-fold increase in EC50) and Lestaurtinib (2.6 to 3.3-fold increase in
EC50). The changes in EC50 in response to AZD1480 were qualitatively similar to
ruxolitinib. Both, the Y931C and G935R mutations had the highest EC50 values (>10μM),
corresponding to a >7-fold increase in EC50. Also, like ruxolitinib, lower EC50 values for
AZD1480 were found with R938L, I960V and E985K (5.6 to 6.5-fold increase) mutation
containing cells.
Ruxolitinib resistance confers a growth advantage during JAK2 inhibition
In order to further confirm the growth advantage of resistant mutations in the presence of
ruxolitinib, we cocultured JAK2V617F expressing cells with a defined amount of cells
containing the E985K or Y931C mutation (1% of total). These mutants were chosen due to
their likely different mode of interaction with JAK2 inhibitors. Under these conditions,
neither mutation could be detected by sequencing of the genomic DNA at the beginning of
the assay (Figure 3A, top panel). Subsequently, cells were grown for seven days in the
presence of solvent (DMSO) or ruxolitinib (300 nM). Our previous experiments suggest that
this concentration is sufficient to significantly, but not completely, impair viability (not
shown) and cell growth (Figure 2A) in parental cells, whereas mutant expressing cells are
unaffected in a three day culture. Sequencing of genomic DNA revealed that seven days
after treatment with ruxolitinib, more than half of the sequence material contained the
E985K or Y931C mutation, but not the control treated cells (Figure 3A, bottom panel). We
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also confirmed the efficacy of ruxolitinib at this concentration by measuring changes in
phosphorylation of the JAK2 target STAT5. Ruxolitinib failed to inhibit phosphorylation of
STAT5 at its activation site in both of the resistant cell lines, but not in JAK2V617F
expressing cells (Figure 3B). These data would support our findings that both mutations
specifically cause ruxolitinib resistance at low doses.
The ‘gatekeeper’ M929I mutation specifically alters ruxolitinib sensitivity
Previously, mutations of the so called ‘gatekeeper’ site in the hinge region of various
tyrosine kinases, including ABL (T315), EGFR (T790), KIT (T670) and PDGFRα (T674),
were associated with strong in vitro and in vivo resistance to their respective
inhibitors 19-21, 23. Our screen did not reveal prominent mutations at this site that could be
detected with our approach. Structural analysis (not shown) and sequence alignment (Table
1) indicate that M929 in human and murine JAK2 was homologous to the T315I gatekeeper
site in ABL and other tyrosine kinases. In these kinases the valine or threonine residues were
commonly mutated into either isoleucine or methionine. In JAK2, this site already contained
a methionine residue in the ‘gatekeeper’ position and we therefore mutated it into isoleucine.
Similar to the experiments above, we determined the dose dependent reduction in growth in
response to various JAK2 inhibitors and calculated EC50 values (Figure 3C). As expected,
we did not observe any change in sensitivity of the M929I mutation towards CYT-387,
TG101348, AZD1480 or lestaurtinib. Interestingly, this assay demonstrated that the M929I
mutation only displayed resistance to ruxolitinib (4.3-fold increase in EC50). The sidechain
of M929 does not have apparent polar contacts with ruxolitinib, but is at the far end of the
hydrophobic groove that binds the kinase inhibitors and may influence the correct
positioning of the drug in the hydrophobic binding pocket.
Discussion
Secondary resistance is a major obstacle in the treatment of cancers that are transformed by
tyrosine kinase oncogenes. Resistant mutations frequently occur at the drug binding site of
the targeted kinases 19-23. In this study, we identified five different point mutations in the
kinase domain of JAK2V617F in an in vitro screen that conferred resistance to the ATP
competitive JAK2 inhibitor ruxolitinib and cross-resistance to CYT-387, TG101348,
AZD1480 and lestaurtinib. These point mutations affected the sensitivity to ruxolitinib and
offered a growth advantage to cells during treatment, compared to native JAK2V617F
expressing cells. Even though our results were obtained with JAK2V617F, it is likely that
other activated forms of JAK2 or oncogenes that lead to activation of JAK2 may as well be
susceptible to mutations that cause resistance. Additional activated forms of JAK2 include
oncogenic fusions, such as PCM1-JAK2 as a consequence of a recurrent t(8;9)(p21;p24) or
point mutations at sites different from V617, such as the R683G mutation in Down
syndrome children with B-progenitor acute lymphoblastic leukemias (B-ALL), additional
JAK2 point mutations in pediatric or adult B-ALL and others 29-32. Further, oncogenic
cytokine receptors, including CRLF2 in B-ALL can lead to constitutive JAK2 signaling 32.
There may be substantial overlap in JAK2 signaling and analogous mutations in the JAK2
kinase domain would be predicted to cause drug resistance similar to the results observed in
our study.
The docking analysis of ruxolitinib to the JAK2 kinase domain suggests that the interaction
within the binding pocket may be similar among different inhibitors, which would explain
cross-resistance. One would expect any mutation that weakens the hydrophobic interactions
or pushes a charged sidechain into the middle of the binding pocket to lead to resistance.
The Y931C mutation may disrupt hydrophobic interactions between Y931 and the ring
structures of the inhibitor, along with other hydrophobic interactions, which are likely
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required to hold the inhibitor in the binding pocket, eventually weakening the inhibitor
binding. This mutation may also change the mainchain conformation in the hinge region,
which could disrupt polar contacts that the inhibitor makes with the mainchain atoms in the
hinge region. Loss of possible π–π interaction between Y931 and pyrazole ring structure
may also result in easy expulsion of the inhibitor from the pocket. The large charged
sidechain of the G935R mutation may reduce or prevent entry of inhibitors. The positive
charge may result in inhibitor expulsion due to charge-charge repulsion with the amine
groups in the inhibitor. We hypothesize that the R938L and I960V mutations change the
mainchain conformation in a way that effect the receptor binding and affinity, due to their
proximity to the binding pocket. The E985K mutation may disturb the water-inhibitor
interactions in the pocket or may disturb the hydrophobic pocket in a way to reduce or
prevent inhibitor binding.
This screen identified a limited number of mutations that resulted in drug resistance. There
are additional amino acids involved in drug interactions and mutations in any of these amino
acids in the N-terminal lobe (A880, L855, V863, V911), C-terminal lobe (L983, R980,
N981), activation loop (D994) or hinge region (Y931, L932) would have the potential to
change the affinity of ruxolitinib or related JAK2 inhibitors to the binding pocket and thus
alter sensitivity. The mechanisms involved may be similar between JAK2 inhibitors.
Nevertheless, our data also suggest that there are differences between ruxolitinib and the
other JAK2 inhibitors. Introduction of the M929I ‘gatekeeper’ mutation specifically affected
ruxolitinib sensitivity. This mutation is homologous to the T315I mutation in BCR-ABL,
which causes strong ABL inhibitor resistance in chronic myelogenous leukemia 20, 22. The
small change in sensitivity for ruxolitinib (4-fold increase in EC50) may be a result of the
bulky methionine residue already present in this location and the change to isoleucine is
rather modest. Thus, the isoleucine residue may provide little hindrance for the overall
binding of specific JAK2 inhibitors, with the exception of ruxolitinib.
In addition, activating mutations in the ABL tyrosine kinase have been implicated in
resistance mechanisms towards imatinib 33. Mutations in the kinase domain were not only
found to confer resistance but also led to constitutive activation of ABL itself. The activating
V617F mutation in the pseudokinase domain does not cause apparent resistance to kinase
inhibitors, but there are other activating sites in the pseudokinase domain 34. A screen for
JAK1 gain-of-function mutation suggests that homologous activating mutation in the
pseudokinase domain may not result in drug resistance 35. This is in contrast to activating
mutations in the JAK1 kinase domain, which can confer resistance. Interestingly, one of
these JAK1 kinase domain substitutions was also introduced into JAK2. This Y931C
mutation is identical to one of the mutations identified in our screen and resulted in factor
independent growth as well as JAK2 inhibitor resistance 35. These results do not exclude the
possibility that additional mutations outside of the kinase domain may decrease sensitivity
for JAK2 inhibitors but our in vitro results hint at mutations in this domain at additional sites
as a potential major cause for secondary resistance.
JAK2 inhibitors have shown promising results during their initial clinical trials in MPN
patients, but their mechanism of action is still not entirely understood. Even through
inhibition of JAK2 plays a major role in the clinical response, there are also effects
independent of JAK2 mutation 7, 8. It has been suggested that ruxolitinib may target
cytokine signaling though inhibition of JAK2 as well as JAK1 7. Thus, combination of
highly specific JAK2 inhibitors with JAK1 inhibitors may be beneficial for MPN patients.
Expanded clinical trials and clinical practice will show whether secondary resistance occurs
in MPNs, but lessons learned from imatinib resistance in chronic myelogenous leukemia
suggest that increased oxidative stress may play a major factor in this process 36, 37. At least
in cell line models, JAK2V617F is associated with increased levels of reactive oxygen
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species (ROS) 26, 38, further underlining the need to carefully monitor the mutational status
of JAK2 (and JAK1) in patients that fail to respond to ruxolitinib and other JAK2 inhibitors.
Our study may help to identify patients that fail to respond to novel JAK2 inhibitors and
require alternative targeted therapies. In particular drugs that target JAK2 maturation (e.g.
HSP90 inhibitors 39) or inhibit JAK2 downstream signaling (e.g. Pim kinase inhibitors 6, 40)
would be of interest and deserve consideration in this patient group.
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Figure 1. Structural analysis of JAK2V617F kinase domain mutations
A, cartoon and transparent surface representation of ruxolitinib-docked JAK2 kinase domain
(A and B) (left) and JAK2 with location of point mutations that lead to drug resistance
(right). N-terminal lobe (salmon), C-terminal lobe (grey), glycine loop (purple), activation
loop (blue) and hinge region (red) form the boundaries for the binding site of ruxolitinib
(stick representation in yellow (carbon) and blue (nitrogen)). The I960V sidechain (purple)
is buried within the protein interior. B, enlarged ruxolitinib binding pocket with secondary
structure elements (cartoon) and the interactions of the sidechains (labeled sticks) with the
inhibitor. Hydrogen-bonds between the inhibitor and the protein are indicated as dotted
yellow lines (one hydrogen-bond between backbone of Y931 and L932; and two hydrogen-
bonds with R980 and N981 and pyrrolopyrimidine ring of the inhibitor; additional hydrogen
bonds are with water molecules (cyan spheres)). Mutated amino acids are labeled red (right
panels). C, surface electrostatic potential representation of the native (left) and G935R
(right) containing JAK2 JH1 domain with ruxolitinib. Charged surfaces are displayed in
shades of blue (positive), red (negative) and white (non-polar).
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Figure 2. Mutations in the JAK2V617F kinase domain confer resistance to JAK2 tyrosine kinase
inhibitors
Growth of BaF3.EpoR cells expressing JAK2V617F (◆) and the additional Y931C (□),
G935R (△)), R938L (×), I960V (○) or E985K (◊) mutations was determined in response to
ruxolitinib (A) or CYT-387, TG101348, AZD1480 and lestaurtinib (B) at various
concentrations, as indicated (n=4). Changes in growth in response to JAK2 inhibitors were
calculated relative to cells that were treated with the solvent DMSO.
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Figure 3. Characterization of ruxolitinib resistant JAK2V617F mutations
A, genomic DNAs from a polyclonal population of BaF3.EpoR.JAK2V617F cells,
containing 1% of JAK2V617F mutant expressing cells were analyzed at day 0 and day 7
after treatment with either DMSO (control) or ruxolitinib (300nM) for the presence of
E985K and Y931C substitution (arrows indicate position of corresponding base
substitution). Partial chromatograms of the forward strand are shown. B, expression of
STAT5, phospho-Y694 STAT5 and β-actin was determined by immunoblotting in
BaF3.EpoR cells expressing either JAK2V617F (control) and cells containing the additional
E985K or Y931C mutation. Cells were either treated with DMSO or 300 nM ruxolitinib. C,
relative changes in EC50 values were determined in response to ruxolitinib for
BaF3.EpoR.JAK2V617F.M929I cells, relative to cells expressing native JAK2V617F.
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Table 1
Sequence alignment of the ‘gatekeeper’ region of tyrosine kinases with common mutations that confer drug
resistance compared to JAK2.
Tyrosine kinase Protein sequence ‘Gatekeeper’ mutation
ABL PFYIIT315EFMTYGNLLDYLR T315I 20
EGFR TVQLIT790QLMPFGCLLDYVR T790M 21
KIT PTLVIT670EYCCYGDLLNFLR T670I 23
PDGFRα PIYIIT674EYCFYGDLVNYLH T674I 19
hJAK2 NLKLIM929EYLPYGSLRDYLQ
mJAK2 --R---929-------------
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